Skip to main content
Log in

Therapeutic Drug Monitoring of Anticonvulsants

State of the Art

  • Drug Concentration Monitoring
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

There is considerable interindividual variation in the relationship between control of seizures and the serum anticonvulsant concentration. The minimum effective serum concentration is dependent on the type and severity of the epilepsy, and varies from patient to patient. The therapeutic range should be used as a guide to adjust the dose in order to further improve seizure control or reduce toxicity; the latter is more likely with higher serum concentrations, but can also be present when concentrations are low. A request for the serum concentration of an anticonvulsant should be made only for good clinical reasons, and an interpretation of that concentration can only be made if all the relevant clinical details are available.

Indications for the measurement of serum anticonvulsant concentrations include poor seizure control, toxicity, suspected gross noncompliance, status epilepticus and the elapse of 2 to 4 weeks after the initiation of therapy. Additional drug therapy, pregnancy or illness may alter drug disposition in a well controlled patient and therapeutic drug monitoring may, therefore, help to prevent seizures secondary to these changes. The measurement of anticonvulsants in saliva as opposed to serum may be of benefit in some patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Albani M. An effective dose schedule for phenytoin treatment of status epilepticus in infancy and childhood. Neuropadiatrie 8: 286–292, 1977

    Article  PubMed  CAS  Google Scholar 

  • André M, Boutroy MJ, Dubruc C, Thenot JP, Bianchetti G, et al. Clonazepam pharmacokinetics and therapeutic efficacy in neonatal seizures. European Journal of Clinical Pharmacology 30: 585–589, 1986

    Article  PubMed  Google Scholar 

  • Bartels H. Rational usage of therapeutic drug monitoring in anti-epileptic treatment. European Journal of Pediatrics 133: 193–199, 1980

    Article  PubMed  CAS  Google Scholar 

  • Beardsley RS, Freeman JM, Appel FA. Anticonvulsant serum levels are useful only if the physician appropriately uses them: an assessment of the impact of providing serum level data to physicians. Epilepsia 24: 330–335, 1983

    Article  PubMed  CAS  Google Scholar 

  • Blennow G. Adverse effects from the circadian fluctuations of carbamazepine plasma levels. Acta Paediatrica Scandinavica 72: 397–401, 1983

    Article  PubMed  CAS  Google Scholar 

  • Blomquist HK, Zetterlund B. Evaluation of treatment in typical absence seizures. Acta Paediatrica Scandinavica 74: 409–415, 1985

    Article  PubMed  CAS  Google Scholar 

  • Booker HE, Darcey B. Serum concentrations of free diphenyl-hydantoin and their relationship to clinical intoxication. Epilepsia 14: 177–184, 1973

    Article  PubMed  CAS  Google Scholar 

  • Borofsky LG, Louis S, Kutt H. Diphenylhydantoin in children. Pharmacology and efficacy. Neurology 23: 967–972, 1973

    Article  PubMed  CAS  Google Scholar 

  • Borofsky LG, Louis S, Kutt H, Roginsky M. Diphenylhydantoin: efficacy, toxicity, and dose-serum level relationships in children. Journal of Pediatrics 81: 995–1002, 1972

    Article  PubMed  CAS  Google Scholar 

  • Braathen G, Theorell K, Persson A, Rane A. Valproate in the treatment of absence epilepsy in children: a study of dose-response relationships. Epilepsia 29: 548–552, 1988

    Article  PubMed  CAS  Google Scholar 

  • Browne TR, Dreifuss FE, Dyken PR, Goode DJ, Penry JK, et al. Ethosuximide in the treatment of absence (petit mal) seizures. Neurology 25: 515–524, 1975

    Article  PubMed  CAS  Google Scholar 

  • Buchanan RA, Allen RJ. Diphenylhydantoin (Dilantin) and phenobarbital blood levels in epileptic children. Neurology 21: 866–871, 1971

    Article  PubMed  CAS  Google Scholar 

  • Buchthal F, Svensmark O. Serum concentrations of diphenylhydantoin (phenytoin) and phenobarbital and their relation to therapeutic and toxic effects. Psychiatria, Neurologia, Neurochirurgia 74: 117–136, 1971

    PubMed  CAS  Google Scholar 

  • Buchthal F, Svensmark O, Schiller PJ. Clinical and electroence-phalographic correlations with serum levels of diphenylhydantoin. Archives of Neurology 2: 624–630, 1960

    Article  PubMed  CAS  Google Scholar 

  • Callaghan N, Kenny RA, O’Neill B. Crowley M, Goggin T. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously unrelated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry 48: 639–644. 1985

    Article  CAS  Google Scholar 

  • Callaghan N, O’Callaghan M, Duggan B, Feely M. Carbamazepine as a single drug in the treatment of epilepsy. Journal of Neurology. Neurosurgery, and Psychiatry 41: 907–912, 1978

    Article  CAS  Google Scholar 

  • Cereghino JJ. Brock JT. van Meter JC. Penry JK. Smith LD. et al. Carbamazepine for epilepsy: a controlled prospective evaluation. Neurology 24: 401–410. 1974

    Article  PubMed  CAS  Google Scholar 

  • Chadwick D. Shaw MDM. Foy P. Rawlins MD. Turnbull DM. Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. Journal of Neurology. Neurosurgery, and Psychiatry 47: 642–644. 1984

    Article  CAS  Google Scholar 

  • Chen S-S, Perucca E. Lee J-N. Richens A, Serum protein binding and free concentration of phenytoin and phenobarbitone in pregnancy. British Journal of Clinical Pharmacology 13: 547–552. 1982

    PubMed  CAS  Google Scholar 

  • Choonara IA. Anliconvulsant toxicity in paediatric out-patients. British Journal of Clinical Practice 42: 21–23. 1988a

    PubMed  CAS  Google Scholar 

  • Choonara IA. The value of serum anticonvulsant levels in paediatric outpatients. British Journal of Clinical Pharmacology 26: 233P. 1988b

    Google Scholar 

  • Cranford RE. Leppik IE. Patrick B. Anderson CB, Kostick B. Intravenous phenytoin in acute treatment of seizures. Neurology 29: 1474–1479. 1979

    Article  PubMed  CAS  Google Scholar 

  • Dam M. Christiansen J. Munck O, Mygind Kl. Antiepilcptic drugs: metabolism in pregnancy. Clinical Pharmacokinetics 4: 53–62. 1979

    Article  PubMed  CAS  Google Scholar 

  • Dam M. Jensen A, Christiansen J. Plasma level and effect of carbamazepine in grand mal and psychomotor epilepsy. Acta Neurologica Scandinavica 75 (Suppl. 60): 33–38. 1975

    Article  Google Scholar 

  • Dawson KP. Jamieson A. Value of blood phenytoin estimation in management of childhood epilepsy. Archives of Disease in Childhood 46: 386–388. 1971

    Article  PubMed  CAS  Google Scholar 

  • Dreifuss FE. Penry JK. Rose SW. Kupferberg HJ. Dyken P. et al. Serum clonazepam concentrations in children with absence seizures. Neurology 25: 255–258. 1975

    Article  PubMed  CAS  Google Scholar 

  • Durelli L, Mutani R. Sechi GP. Monaco F, Glorioso N. et al. Cardiac side effects of phenytoin and carbamazepine. Archives of Neurology 42: 1067–1068. 1985

    Article  PubMed  CAS  Google Scholar 

  • Feldman RG. Pippenger CE. The relation of anticonvulsant drug levels to complete seizure control. Journal of Clinical Pharmacology 16: 51–59. 1976

    PubMed  CAS  Google Scholar 

  • Friedman IM. Litt IF. Henson R. Holtzman D. Halverson D. Saliva phenobarbital and phenyloin concentrations in epileptic adolescents. Journal of Pediatrics 98: 645–647. 1981

    Article  PubMed  CAS  Google Scholar 

  • Froscher W. Eichclbaum M. Gugler R. Hildenbrand G. Penin H. A prospective randomised trial on the effect of monitoring plasma anticonvulsant levels in epilepsy. Journal of Neurology 224: 193–201. 1981

    Article  PubMed  CAS  Google Scholar 

  • Fung K. Ueda K. Saliva and serum valproic acid levels in epileptic children. Jurnal of Pediatrics 100: 512. 1982

    Article  CAS  Google Scholar 

  • Gal P. Toback J. Boer HR. Erkan NV. Wells TJ. Efficacy of phenobarbital monotherapy in treatment of neonatal seizures- relationship to blood levels. Neurology 32: 1401–1404. 1982

    Article  PubMed  CAS  Google Scholar 

  • Gallagher BB. Baumel IP. Mattson RH. Woodbury SG. Primi-done, diphenylhydantoin and phenobarbital. Neurology 23: 145–149. 1973

    Article  PubMed  CAS  Google Scholar 

  • Gamstorp I. Treatment with carbamazepine: children. Advances in Neurology 11: 237–248. 1975

    PubMed  CAS  Google Scholar 

  • Gannaway DJ. Mawer GE. Serum phenytoin concentration and clinical response in patients with epilepsy. British Journal of Clinical Pharmacology 12: 833–839. 1981

    Article  PubMed  CAS  Google Scholar 

  • Gilman JT. Gal P. Dunchowny MS. Weaver RL. Ransom JL. Rapid sequential phenobarbital treatment of neonatal seizures. Pediatrics 83: 674–678. 1989

    PubMed  CAS  Google Scholar 

  • Gram L. Flachs H. Wurtz-Jorgensen A. Parnas J. Andersen B. Sodium valproate, serum levels and clinical effect in epilepsy: a controlled study. Epilepsia 20: 303–312. 1979

    Article  PubMed  CAS  Google Scholar 

  • Gugler R. von Uuruh GE. Clinical Pharmacokinetics of valproic acid. Clinical Pharmacokinetics 5: 67–83. 1980

    Article  PubMed  CAS  Google Scholar 

  • Haerer AF. Grace JB. Studies of anticonvulsant levels in epileptics. Acta Neurologica Scandinavica 45: 18–31. 1969

    Article  PubMed  CAS  Google Scholar 

  • Haigh D. Forsythe WI. The treatment of childhood epilepsy with sodium valproate. Developmental Medicine and Child Neurology 17: 743–748. 1975

    Article  PubMed  CAS  Google Scholar 

  • Herngren L, Nergardh A. Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy. Journal of Neurology 235: 491–495. 1988

    Article  PubMed  CAS  Google Scholar 

  • Herranz JL. Armijo JA, Arteaga R. Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children. Epilepsia 29: 794–804. 1988

    Article  PubMed  CAS  Google Scholar 

  • Herranz JL. Arteaga R, Armijo JA. Side effects of sodium valproate in monotherapy controlled by plasma levels: a study in 88 pédiatrie patients. Epilepsia 23: 203–214. 1982

    Article  PubMed  CAS  Google Scholar 

  • Hogstedt S. Lindberg B, Rane A. Increased oral clearance of metoprolol in pregnancy. European Journal of Clinical Pharmacology 24: 217–220. 1983

    Article  PubMed  CAS  Google Scholar 

  • Hoppener RJ. Kuyer A. Meijer JWA, Hulsman J. Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia 21: 341–350. 1980

    Article  PubMed  CAS  Google Scholar 

  • Jailing B. Plasma concentrations of phenobarbital in the treatment of seizures in newborns. Acta Paediatrica Scandinavica 64: 514–524. 1975

    Article  Google Scholar 

  • Jeavons PM. Clark JE. Maheshwari MC. Treatment of generalized epilepsies of childhood and adolescence with sodium valproate. Developmental Medicine and Child Neurology 19: 9–25. 1977

    Article  PubMed  CAS  Google Scholar 

  • Klotz U. Schweizer C. Valproic acid in childhood epilepsy: an-ticonvulsive efficacy in relation to its plasma levels. International Journal of Clinical Pharmacology. Therapy and Toxicology 18: 461–465. 1980

    CAS  Google Scholar 

  • Knight AH. Rhind EG. Epilepsy and pregnancy: a study of 153 pregnancies in 59 patients. Epilepsia 16: 99–110. 1975

    Article  PubMed  CAS  Google Scholar 

  • Knott C. Williams CP. Reynolds F. Phenytoin kinetics during pregnancy and the puerpenum. British Journal of Obstetrics and Gynaecology 93: 1030–1037. 1986

    Article  PubMed  CAS  Google Scholar 

  • Knudsen FU. Optimum management of febrile seizures in childhood. Drugs 36: 111–120. 1988

    Article  PubMed  CAS  Google Scholar 

  • Kutt H. Winters W. Kokenge R. McDowell F. Diphenylhydan-toin metabolism, blood levels and toxicity. Archives of Neurology 11: 642–648. 1964

    Article  PubMed  CAS  Google Scholar 

  • Levy LL. Fenichel GM. Diphenylhydantoin activated seizures. Neurology 15: 716–722. 1965

    Article  PubMed  CAS  Google Scholar 

  • Lockman LA, Kriel R. Zaske D. Thompson T. Virnig N. Phenobarbital dosage for control of neonatal seizures. Neurology 29: 1445–1449. 1979

    Article  PubMed  CAS  Google Scholar 

  • Lund L. Anticonvulsant effect of diphenylhydantoin relative to plasma levels. Archives of Neurology 31: 289–294, 1974

    Article  PubMed  CAS  Google Scholar 

  • McAuliffe JJ. Sherwin AL. Leppik IE. Fayle SA. Pippenger CE. Salivary levels of anticonvulsants: a practical approach to drug monitoring. Neurology 27: 409–413. 1977

    Article  PubMed  CAS  Google Scholar 

  • Minns RA. Brown JK. Blackwood DHR. McQueen JK. Valproate levels in children with epilepsy. Lancet 1: 677–678. 1982

    PubMed  CAS  Google Scholar 

  • Mucklow JC. Dollery CT. Compliance with anticonvulsant therapy in a hospital clinic and in the community. British Journal of Clinical Pharmacology 6: 75–79. 1978

    Article  PubMed  CAS  Google Scholar 

  • Naito H. Wachi M. Nishida M. Clinical effects and plasma concentrations of long-term clonazepam monotherapy in previously untreated epileptics. Acta Neurologica Scandinavica 76: 58–63. 1987

    Article  PubMed  CAS  Google Scholar 

  • Norell E. Lilienberg G. Gamstorp I. Systematic determination of the serum phenytoin level as an aid in the management of children with epilepsy. European Neurology 13: 232–244. 1975

    Article  PubMed  CAS  Google Scholar 

  • North JB. Hanieh A. Challen RG. Penhall RK. Hann CS. et al. Postoperative epilepsy: a double-blind trial of phenytoin after craniotomy. Lancet 1: 384–386. 1980

    Article  PubMed  CAS  Google Scholar 

  • O’Dougherty M, Wright FS. Cox S. Walson P. Carbamazepine plasma concentration: relationship to cognitive impairment. Archives of Neurology 44: 863–867. 1987

    Article  PubMed  Google Scholar 

  • Painter MJ. Pippenger C. MacDonald H. Pitlick W. Phenobarbital and diphenylhydanloin levels in neonates with seizures. Journal of Pediatrics 92: 315–319. 1978

    Article  PubMed  CAS  Google Scholar 

  • Park BK. Kitleringham NR. Adverse reactions and drug metabolism. Adverse Drug Reaction Bulletin 122: 456–459, 1987

    Article  Google Scholar 

  • Patsalos PN. Stephenson TJ. Krishna S. Elyas AA. Lascelles PT. et al. Side-effects induced by carbamazcpine-10.11-epoxidc. Lancet 2: 496. 1985

    Article  PubMed  CAS  Google Scholar 

  • Pearson RM. Who is taking their tablets?. British Medical Journal 285: 757–758. 1982

    Article  PubMed  CAS  Google Scholar 

  • Pippenger CE. Rosen TS. Phenobarbital plasma levels in neonates. Clinics in Perinalology 2: 111–115. 1975

    CAS  Google Scholar 

  • PF. Maclaine NG. Scott DF. Laurance BM. Tonic status epilepticus precipitated by intravenous diazepam in a child with petil mal status. Epilepsia 13: 467–472. 1972

    Article  PubMed  Google Scholar 

  • Rane A. Hojer B. Wilson JT. Kinetics of carbamazepine and its 10.11-epoxide in children. Clinical Pharmacology and Therapeutics 19: 276–283. 1976

    PubMed  CAS  Google Scholar 

  • Reynolds EH. Shorvon SD. Monotherapy or polytherapy for epilepsy?. Epilepsia 22: 1–10. 1974

    Article  Google Scholar 

  • Reynolds EH. Shorvon SD. Galbraith AW. Chadwick D. Dellaportas CI. et al. Phenytoin monotherapy for epilepsy: a long-term prospective study, assisted by serum level monitoring, in previously untreated patients. Epilepsia 22: 475–488, 1981

    Article  PubMed  CAS  Google Scholar 

  • Riva R. Contin M. Albani F. Perucca E. Ambrosetto G, et al. Lateral gaze nystagmus in carbamazepine-treated epileptic patients: correlation with total and free plasma concentrations of parent drug and its 10.11-epoxidc metabolite. Therapeutic Drug Monitoring 7: 277–282. 1985

    Article  PubMed  CAS  Google Scholar 

  • Rowan AJ. Binnie CD. Warfleld CA. Meinardi H. Meijer JWA. The delayed effect of sodium valproate on the photoconvul-sive response in man. Epilepsia 20: 61–68, 1979

    Article  PubMed  CAS  Google Scholar 

  • Ruuskanen I. Kilpeläinen HO. Riekkinen PJ. Side effects of sodium valproate during long-term treatment in epilepsy. Acta Neurologica Scandinavica 60: 125–128. 1979

    Article  PubMed  CAS  Google Scholar 

  • Rylance GW. Moreland TA. Saliva carbamazepine and phenytoin level monitoring. Archives of Disease in Childhood 56: 637–652. 1981

    Article  PubMed  CAS  Google Scholar 

  • Salem RB. Wilder BJ. Yost RL. Doering PL, Lee C. Rapid infusion of phenytoin sodium loading doses. American Journal of Hospital Pharmacy 38: 354–357. 1981

    PubMed  CAS  Google Scholar 

  • Scheffner D. König S, Rauterberg-Ruland I. Kochen W, Hofmann WJ. et al. Fatal liver failure in 16 children with valproate therapy. Epilepsia 29: 530–542. 1988

    Article  PubMed  CAS  Google Scholar 

  • Schmidt D. Canger R. Avanzini G, Battino D. Cusi C. et al. Change of seizure frequency in pregnant epileptic women. Journal of Neurology, Neurosurgery and Psychiatry 46: 751–755. 1983

    Article  CAS  Google Scholar 

  • Schmidt D. Einicke I. Haenel F. The influence of seizure type on the efficacy of plasma concentration of phenytoin, phenobarbital and carbamazepine. Archives of Neurology 43: 263–265, 1986

    Article  PubMed  CAS  Google Scholar 

  • Schobben F. van der Kleijn E, Vree TB. Therapeutic monitoring of valproic acid. Therapeutic Drug Monitoring 2: 61–71, 1980

    Article  PubMed  CAS  Google Scholar 

  • Schoeman JF, Elyas AA, Brett EM. Lascelles PT. Correlation between plasma carbamazepine-10.11 -epoxide concentration and drug side-effects in children with epilepsy. Developmental Medicine and Child Neurology 26: 756–764. 1984

    Article  PubMed  CAS  Google Scholar 

  • Sherwin AL, Robb JP, Lechter M. Improved control of epilepsy by monitoring plasma elhosuximide. Archives of Neurology 28: 178–181, 1973

    Article  PubMed  CAS  Google Scholar 

  • Shields WD. Saslow E. Myoclonic, atonic and absence seizures following institution of carbamazepine therapy in children. Neurology 33: 1487–1489. 1983

    Article  PubMed  CAS  Google Scholar 

  • Shorvon SD. Chadwick D. Galbraith AW, Reynolds EH. One drug for epilepsy. British Medical Journal 1: 474–476. 1978

    Article  PubMed  CAS  Google Scholar 

  • Snead OC. Hosey LC. Exacerbation of seizures in children by carbamazepine. New England Journal of Medicine 313: 916–921. 1985

    Article  PubMed  Google Scholar 

  • Stilman N. Masdeu JC. Incidence of seizures with phenytoin toxicily. Neurology 35: 1769–1772, 1985

    Article  PubMed  CAS  Google Scholar 

  • Strandjord RE. Johannessen SI. Single-drug therapy with carbamazepine in patients with epilepsy: serum levels and clinical effect. Epilepsia 21: 655–662, 1980

    Article  PubMed  CAS  Google Scholar 

  • Ståhl Y, Persson A. Petters I. Rane A, Theorell K. et al. Kinetics of clonazepam in relation to EEG and clinical effects. Epilepsia 24: 225–231. 1983

    Article  PubMed  Google Scholar 

  • Thompson PJ, Trimble MR. Anticonvulsant drugs and cognitive functions. Epilepsia 23: 531–544, 1982

    Article  PubMed  CAS  Google Scholar 

  • Tokugawa K. Ueda K, Fujito H, Kurokawa T. Correlation between the saliva and free serum concentration of phenobarbital in epileptic children. European Journal of Pediatrics 145: 401–402, 1986

    Article  PubMed  CAS  Google Scholar 

  • Tomson T. Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Archives of Neurology 41: 830–834. 1984

    Article  PubMed  CAS  Google Scholar 

  • Troupin A, Ojemann LM. Paradoxical intoxication — a complication of anticonvulsant administration. Epilepsia 16: 753–758, 1975

    Article  PubMed  CAS  Google Scholar 

  • Troupin A, Ojemann LM, Halpern L, Dodrill C, Wilkus R, et al. Carbamazepine — a double-blind comparison with phenytoin. Neurology 27: 511–519, 1977

    Article  PubMed  CAS  Google Scholar 

  • Turnbull DM, Rawlins MD, Weightman D. Chadwick DW. Plasma concentrations of sodium valproate: their clinical value. Annals of Neurology 14: 38–42. 1983

    Article  PubMed  CAS  Google Scholar 

  • Turnbull DM. Rawlins MD. Weightman D, Chadwick DM. ’Therapeutic’ serum concentration of phenytoin: the influence of seizure type. Journal of Neurology. Neurosurgery and Psychiatry 47: 231–234, 1984

    Article  CAS  Google Scholar 

  • Vajda FJE, Aicardi J. Reassessment of the concept of a therapeutic range of anticonvulsant plasma levels. Developmental Medicine and Child Neurology 25: 660–671. 1983

    Article  PubMed  CAS  Google Scholar 

  • Wallis W, Kutt H. McDowell F. Intravenous diphenylhydantoin in treatment of acute repetitive seizures. Neurology 18: 513–525, 1968

    Article  PubMed  CAS  Google Scholar 

  • Wilson JT, Höjer B. Tomson G, Rane A. Sjoqvist F. High incidence of a concentration-dependent skin reaction in children treated with phenytoin. British Medical Journal 1: 1583–1586. 1978

    Article  PubMed  CAS  Google Scholar 

  • Wing DS, Duff HJ. The impact of a therapeutic drug monitoring program for phenytoin. Therapeutic Drug Monitoring 11: 32–37, 1989

    Article  PubMed  CAS  Google Scholar 

  • Woo E, Chan YM, Yu YL, Chan YW, Huang CY. If a well-stabilized epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased?. A randomized prospective study. Epilepsia 29: 129–139. 1988

    CAS  Google Scholar 

  • Yerby MS, Friel PN. Miller DQ. Carbamazepine protein binding and disposition in pregnancy. Therapeutic Drug Monitoring 7: 269–273, 1985

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Choonara, I.A., Rane, A. Therapeutic Drug Monitoring of Anticonvulsants. Clin Pharmacokinet 18, 318–328 (1990). https://doi.org/10.2165/00003088-199018040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199018040-00004

Keywords

Navigation